Bio-Techne Corporation

Equities

TECH

US09073M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
57.44 ^USD	-2.13%		-2.35%	-20.26%

Dec. 12	Deutsche Bank Adjusts Price Target on Bio-Techne to $72 From $66, Maintains Buy Rating	MT
Dec. 12	Deutsche Bank Raises Price Target on Bio-Techne to $72 From $66, Keeps Buy Rating	MT

Transcript : Bio-Techne Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 09

Published on 11/12/2024 at 12:30 pm EST

S&P Capital IQ

Presenter Speech
Daniel Leonard (Analysts)

Welcome, everybody, to day one of the UBS Healthcare Conference. I'm Dan Leonard, the life science tools, diagnostics and services analyst at UBS. We're lucky

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Bio-Techne Corporation

Dec. 12	Deutsche Bank Adjusts Price Target on Bio-Techne to $72 From $66, Maintains Buy Rating	MT
Dec. 12	Deutsche Bank Raises Price Target on Bio-Techne to $72 From $66, Keeps Buy Rating	MT
Dec. 11	Bio-Techne Corporation Announces Strategic Collaboration Between One of Its Spatial Biology Brands, Lunaphore, and the Wyss Center for Bio and Neuroengineering	CI
Dec. 11	Bio-Techne's Lunaphore Brand, Wyss Center Geneva Partner Over Automated Workflow Development	MT
Dec. 09	Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis	CI
Dec. 09	Bio-Techne Corporation Presents at 53rd Annual Nasdaq Investor Conference, Dec-09-2025 09:30 AM
Dec. 03	Bio-Techne Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03:15 PM
Dec. 02	Bio-Techne Corporation Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 08:20 AM
Nov. 20	Bio-Techne Corporation Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 12:30 PM
Nov. 20	Argus Adjusts Price Target on Bio-Techne to $68 From $65, Maintains Buy Rating	MT
Nov. 18	Bio-Techne Corporation Presents at Stephens Annual Investment Conference 2025, Nov-18-2025 08:00 AM
Nov. 18	Bio-Techne Licenses AI-Designed NovoBody Duo Molecules From Monod Bio	MT
Nov. 18	Bio-Techne announces licensing agreement with Monod Bio	RE
Nov. 11	Bio-Techne Corporation Presents at Stifel 2025 Healthcare Conference, Nov-11-2025 09:20 AM
Nov. 10	Bio-Techne Corporation Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 10:15 AM
Nov. 06	Wells Fargo Adjusts Bio-Techne Price Target to $70 From $59, Maintains Overweight Rating	MT
Nov. 06	Baird Adjusts Bio-Techne Price Target to $61 From $62, Maintains Neutral Rating	MT
Nov. 06	Stephens Adjusts Bio-Techne Price Target to $70 From $65, Maintains Overweight Rating	MT
Nov. 06	UBS Adjusts Price Target on Bio-Techne to $70 From $65, Maintains Buy Rating	MT
Nov. 05	Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on May 6, 2025.	CI
Nov. 05	Evercore ISI Adjusts Price Target on Bio-Techne to $68 From $72	MT
Nov. 18	Bio-Techne Corporation, Q1 2026 Earnings Call, Nov 05, 2025
Nov. 05	Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025	CI
Nov. 05	Bio-Techne Corporation Reports Earnings Results for the First Quarter Ended September 30, 2025	CI
Nov. 05	Bio-Techne misses quarterly sales estimates on weak biotech demand	RE